QURE 4-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, is intensifying its investigation into uniQure N.V. (NASDAQ: QURE) amid significant FDA criticisms regarding the company's gene therapy candidate, AMT-130. This follows reports from major media outlets where an FDA official labeled the therapy a "failed" product, claiming uniQure's data comparisons were "distorted." The FDA's statement emphasized that the company misrepresented certain clinical requirements, specifically the ethical concerns surrounding sham surgeries, as they clarified the FDA's conditions did not entail invasive procedures.
This escalating scrutiny coincides with a securities class action lawsuit that seeks to represent investors who acquired shares of uniQure between September 24 and October 31, 2025. The lawsuit alleges that uniQure misled investors about its engagements with the FDA and the approval status of its study designs, including using historical data improperly as a control for AMT-130. The allegations suggest a pattern of deception regarding regulatory consensus and a downplayed need for a sham surgery control in clinical trials.
Notably, the investors are reminded that they have until April 13, 2026, to apply to be the Lead Plaintiff in this litigation. Failure to disclose critical information regarding the approval process led to a significant drop in share value after the revelations became public, with uniQure’s stock tumbling by 49% post-announcement. Hagens Berman is urging affected investors to submit their losses and participate in the ongoing investigation.
The firm has a long history of representing clients in complex corporate accountability cases and has achieved notable recoveries in prior litigation efforts. They are asking whistleblowers with undisclosed information about uniQure's practices to come forward, as part of the effort to ensure corporate accountability.
MWN-AI** Analysis
Investors in uniQure N.V. (NASDAQ: QURE) are currently navigating a turbulent landscape, driven by recently disclosed FDA rebukes and a pending securities class action lawsuit. Key allegations include misrepresented interactions with the FDA and the utilization of a pivotal study design that lacked regulatory approval. Such significant claims can drastically affect investor sentiment and stock performance.
The FDA characterized uniQure's lead gene therapy candidate, AMT-130, as a "failed therapy," which raises serious concerns about its future viability and approval prospects. This controversy, coupled with accusations that the company downplayed essential study requirements, has already resulted in substantial declines in share value. On November 3, 2025, when these revelations became public, uniQure's stock plunged nearly 49%.
As of the April 2026 deadline for the lead plaintiff designation in the class action, potential investors and current shareholders should exercise caution. The ongoing investigation by Hagens Berman emphasizes the risks associated with uniQure's claims and the consequences of alleged "distorted" data.
Given the implications of the FDA's statements and the potential for further legal challenges, investors might want to consider the following strategies:
1. **Risk Assessment**: Carefully evaluate your current holdings in QURE. If heavily invested, consider diversifying to mitigate the impact of the forecasted volatility.
2. **Monitoring Developments**: Stay updated on the class action's progress and any further communications from the FDA, as these will be pivotal in shaping market sentiment.
3. **Short-Term Trading**: For those looking to trade, consider employing a short-selling strategy, particularly if stock performance appears to decline further amid legal troubles and negative press.
In summary, while QURE may hold potential long-term, the immediate landscape is fraught with risk. Exercising caution and staying informed is crucial for current and prospective investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit
SAN FRANCISCO, April 9, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
DEEP DIVE ANALYIS: Visit Hagens Berman's dedicated QURE case page: www.hbsslaw.com/cases/uniqure, or view our latest video summary of the allegations: https://youtu.be/VWKl1BzabcE
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 13, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
How might the recent FDA allegations regarding "distorted data" impact the future prospects and valuation of uniQure N.V. QURE, particularly in relation to its lead gene therapy candidate, AMT-130?
What are the key implications of the ongoing securities class action lawsuit for investors in uniQure N.V. QURE, and how could the outcome affect the company's stock performance moving forward?
Given the FDA's public rebuke of uniQure N.V. QURE regarding its clinical study designs, what steps should the company take to restore investor confidence and ensure compliance with regulatory expectations?
How has the market reacted to the information surrounding uniQure N.V. QURE's alleged misrepresentations and the associated risks, especially in light of the recent significant drop in stock price?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
